多发性骨髓瘤患者白细胞介素6水平变化与疗效和预后相关性

目的]评价白细胞介素6（IL-6）、C反应蛋白（CRP）、乳酸脱氢酶（LDH）、β2微球蛋白（β2-MG）作为多发性骨髓瘤（MM）患者疗效和预后判断指标的价值。方法]将17例MMⅢ期患者在中西医结合治疗过程中的110组实验室数据进行线性相关分析，并比较其中8例治疗前后各项指标的水平变化。结果]治疗后IL-6、CRP、β2-MG、CRE、Urea、瘤细胞百分比（BMPC）、本周蛋白较治疗前下降（P〈0．05）;IL-6与CRP、LDH与β2-MG、LDH与本周蛋白、β2-MG与Urea、β2-MG与BMPC有非常显著相关性（P〈0．01，｜r｜〉0．45），IL-6与Ca有显著相关性（P〈0．05，｜r｜〉0．45）。A、B亚型间β2-MG差异非常显著（P〈0．01），但其与BMPC相关性有统计学意义（P〈0．05，｜r｜〉0．45）。结论]IL-6、CRP、β2-MG适合作为MMⅢ期患者疗效和预后的判断指标。

Correlationship between on Interleukine-6 Level and Efficacy and Prognosis of Multiple Myeloma

Purpose] To evaluate the value of interleukine-6（IL-6）, C-reaction protein（CRP）, β2-microglobulin （β2-MG） and laetatede hydrogenase （LDH） in efficacy and prognosis of multiple myeloma （MM） patients. Methods] One handred and ten laboratory data from seventeen stage Ⅲ eases teated with Chinese Medicine and chemotherapy were analyzed for correlation. Eight cases were compared before and after treatment.Results] Levels of IL-6, CRP, CRE, Urea, β2-MG, BMPC and Ben Jones protein significantly reduced after treatment （P〈0.05）. Correlations were found between IL-6 and CRP, β2- MG and LDH, β2-MG and Urea, β2-MG and BMPC, LDH and Ben Jones protein （P〈0.01, ｜r｜〉0.45）, IL-6 and Ca （P〈0.05, ｜r｜〉0.45）. β2-MG levels in 3A and 3B patients were significantly different（P〈0.01, ｜r｜〉 0.45）, and their correlations with BMPC were both significant （P〈0.05, ｜r｜〉0.45）. Conclusion] Levels of IL-6, CRP and β2-MG are suitable efficacy and prognostic factors in stage m multiple myeloma cases.